Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.
about
Novel oral anticoagulants and the 73rd anniversary of historical warfarinNew Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release.Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice.Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillationParenteral administration of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis.Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.New insights into modulation of thrombin formation.Thrombin generation and atherosclerosis.Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.The hemostatic system as a regulator of inflammation in atherosclerosis.Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis.Factor Xa Signaling Contributes to the Pathogenesis of Inflammatory Diseases.Factor Xa induces pro-inflammatory cytokine expression in RAW 264.7 macrophages via protease-activated receptor-2 activation.Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5Local Production of Activated Factor X in Atherosclerotic Plaque Induced Vascular Smooth Muscle Cell Senescence.Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.
P2860
Q26771544-FAD3709B-71D4-4679-99C4-3EC37120D0B2Q28081366-CA7CD072-B44E-411D-86BE-F6C553B96ECFQ34981567-C30D2E0A-70F2-4FA4-BF0E-9608D090AFF5Q35759361-FC51AD8F-D52B-4396-A1C8-5ED76BA383D7Q37293260-56D5D5F6-1739-4F7A-AAC5-B8AD0396CDC3Q37654883-C4FDAEEA-8949-4587-BA91-5FA978FF2F25Q38009353-05C7FAE6-12F0-4742-80AB-FA6960D8BCB7Q38136548-0EFE1BA2-85FD-429F-B8DA-2A7A9AEE6CBCQ38163395-0D42C574-C398-4328-AB6C-D7C5399B6154Q38175362-81C2FDAB-6BD1-4CF7-969F-A639F725FA49Q38285796-6B05DE50-CE67-4325-92C4-60B7A080D4F3Q38851354-8DA77C08-1AA7-43D6-8893-DC246C4B83F4Q39031297-035E08CA-8274-4256-B301-CAB115EF74C9Q40065755-68221BAA-31F2-4FB6-904D-CF8BF4DDE05EQ41484530-0461B829-0CD3-4D89-8609-95CA1A37F6F4Q45875545-45795F66-02F7-486D-B322-A0810E7F0E00Q45937484-33993DA8-CC50-4B6B-A2E7-EFF1288BB3E4Q49960669-E661EB23-C8A5-4BCF-94D1-117327A0DBF3
P2860
Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Evaluation of plaque stability ...... ctor Xa inhibitor rivaroxaban.
@ast
Evaluation of plaque stability ...... ctor Xa inhibitor rivaroxaban.
@en
type
label
Evaluation of plaque stability ...... ctor Xa inhibitor rivaroxaban.
@ast
Evaluation of plaque stability ...... ctor Xa inhibitor rivaroxaban.
@en
prefLabel
Evaluation of plaque stability ...... ctor Xa inhibitor rivaroxaban.
@ast
Evaluation of plaque stability ...... ctor Xa inhibitor rivaroxaban.
@en
P2093
P2860
P356
P1476
Evaluation of plaque stability ...... ctor Xa inhibitor rivaroxaban.
@en
P2093
Berend Isermann
Erwin Blessing
Florian Bea
Hongjie Wang
Hugo A Katus
Khurrum Shahzad
Michael Preusch
Qianxing Zhou
P2860
P304
P356
10.1155/2011/432080
P577
2011-06-07T00:00:00Z